Introduction – Company Background
GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.
With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.
With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.
From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.
At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.
By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.
Core Strengths in Insole Manufacturing
At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.
Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.
We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.
With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.
Customization & OEM/ODM Flexibility
GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.
Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.
With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.
Quality Assurance & Certifications
Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.
We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.
Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.
ESG-Oriented Sustainable Production
At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.
To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.
We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.
Let’s Build Your Next Insole Success Together
Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.
From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.
Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.
🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw
Graphene insole manufacturer in Indonesia
Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.
With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Innovative pillow ODM solution in Taiwan
Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.
We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Taiwan OEM factory for footwear and bedding
At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Custom graphene foam processing China
📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Indonesia OEM factory for footwear and bedding
Recent research discovered several genetic variants linked to mathematical abilities in children, with three specific genes associated with subtraction, spatial conception, and division skills. Researchers Identified Genetic Variations Linked to Specific Math Abilities in Children A recent study published in the journal Genes, Brain and Behavior has uncovered several genetic variations that could be linked with mathematical abilities in children. The research involved conducting genome-wide association studies on 1,146 elementary school students from China, focusing on 11 categories of mathematical ability. The results revealed seven single nucleotide genetic variations in the genome that showed a strong correlation with mathematical and reasoning skills. Additional analyses revealed significant associations of three mathematical ability categories with three genes. Variants in LINGO2 (leucine rich repeat and lg domain containing 2) were associated with subtraction ability, OAS1 (2’-5’-oligoadenylate synthetase 1) variants were associated with spatial conception ability, and HECTD1 (HECT domain E3 ubiquitin protein ligase 1) variants were associated with division ability. “Results of our research provide evidence that different mathematical abilities may have a different genetic basis. This study not only refined genome-wide association studies of mathematical ability but also added some population diversity to the literature by testing Chinese children,” said corresponding author Jingjing Zhao, Ph.D., a professor in the School of Psychology at Shaanxi Normal University, China. Reference: “A genome-wide association study identified new variants associated with mathematical abilities in Chinese children” by Liming Zhang, Zhengjun Wang, Zijian Zhu, Qing Yang, Chen Cheng, Shunan Zhao, Chunyu Liu and Jingjing Zhao, 22 February 2023, Genes, Brain & Behavior. DOI: 10.1111/gbb.12843
Researchers at the University of Florida have utilized CRISPR/Cas9 to modify the leaf angle of sugarcane, significantly enhancing its sunlight capture and biomass yield. This breakthrough in editing the complex, polyploid genome of sugarcane marks a major advancement in crop improvement and biofuel production. Researchers optimized sugarcane’s leaf angle using CRISPR gene editing, enhancing its sunlight absorption. Sugarcane ranks as the top crop globally in terms of biomass yield, contributing to 80 percent of sugar and 40 percent of biofuel production around the world. Its substantial size and optimal utilization of water and light position it as an ideal source for generating innovative renewable bioproducts and biofuels. However, as a hybrid of Saccharum officinarum and Saccharum spontaneum, sugarcane has the most complex genome of all crops. This complexity means that improving sugarcane through conventional breeding is challenging. Because of this, researchers turn to gene editing tools, such as the CRISPR/Cas9 system to precisely target the sugarcane genome for improvement. Eleanor Brant collecting leaf samples for molecular analysis of gene-edited sugarcane. Credit: Charles Keato Innovative Research for Crop Improvement In their new paper, published in Plant Biotechnology Journal, a team of researchers from the University of Florida at the Center for Advanced Bioenergy and Bioproducts Innovation (CABBI) has leveraged this genetic complexity to their advantage to use the CRISPR/Cas9 system to fine-tune leaf angle in sugarcane. These genetic tweaks allowed the sugarcane to capture more sunlight, which in turn increased the amount of biomass produced. This work supports the DOE-funded CABBI Bioenergy Research Center’s “plants as factories” approach and the primary goal of its Feedstock Production research — to synthesize biofuels, bioproducts, and high-value molecules directly in the stems of plants such as sugarcane. The sugarcane genome’s complexity is due in part to its high levels of redundancy: It possesses many copies of each gene. The phenotype that a sugarcane plant displays, therefore, typically depends on the cumulative expression of the multiple copies of a certain gene. The CRISPR/Cas9 system is perfect for this task because it can be designed to edit a few or many copies of a gene at once. Baskaran Kannan evaluating gene-edited sugarcane in the field. Credit: Uzair Khan This study focused on LIGULELESS1, or LG1, a gene that plays a major role in determining leaf angle in sugarcane. Leaf angle, in turn, determines how much light can be captured by the plant, which is critical for biomass production. Since sugarcane’s highly redundant genome contains 40 copies of LG1, the researchers were able to fine-tune the leaf angle by editing different numbers of copies of this gene, resulting in slightly different leaf angles depending on how many copies of LG1 were edited. “In some of the LG1 edited sugarcanes, we just mutated a few of the copies,” said Fredy Altpeter, research team lead and Professor of Agronomy at the University of Florida. “And in doing so, we were able to tailor the leaf architecture until we found the optimal angle that resulted in increased biomass yield.” Field Trial Results and Future Implications When the scientists grew sugarcane in field trials, they found that the upright leaf phenotypes allowed more light to penetrate the canopy, which resulted in increased biomass yield. One sugarcane line in particular, which contained edits in ~12% of the LG1 copies and showed a 56% decrease in leaf inclination angle, had an 18% increase in dry biomass yield. By optimizing sugarcane to capture more light, these gene edits increase biomass yield without having to add more fertilizer to the fields. In addition to that, building a stronger understanding of complex genetics and genome editing helps researchers work toward refined approaches for crop improvement. “This is the first peer-reviewed publication describing a field trial of CRISPR-edited sugarcane,” Altpeter said. “And this work also shows unique opportunities for the editing of polyploid crop genomes, where researchers can fine-tune a specific trait.” Reference: “The extent of multiallelic, co-editing of LIGULELESS1 in highly polyploid sugarcane tunes leaf inclination angle and enables selection of the ideotype for biomass yield” by Eleanor J. Brant, Ayman Eid, Baskaran Kannan, Mehmet Cengiz Baloglu and Fredy Altpeter, 22 May 2024, Plant Biotechnology Journal. DOI: 10.1111/pbi.14380 Co-authors on this study included CABBI researchers at the University of Florida Department of Agronomy, Eleanor Brant, Ayman Eid, Baskaran Kannan, and Mehmet Cengiz Baloglu.
A study led by Harvard Medical School researchers has discovered how bacteria break through the brain’s protective layers to cause meningitis, a highly fatal disease. The researchers found that bacteria exploit nerve cells in the meninges to suppress the immune response, allowing the infection to spread. The study identified a chemical released by nerve cells and an immune cell receptor that, when blocked, can interrupt the cascade and prevent bacterial invasion. If replicated through further research, these findings could lead to therapies for this hard-to-treat condition. The treatments would target the early stages of infection before bacteria can spread deep into the brain. Study shows bacteria hijack crosstalk between nerve and immune cells to cause meningitis. A new study led by researchers at Harvard Medical School details the step-by-step cascade that allows bacteria to break through the brain’s protective layers — the meninges — and cause brain infection, or meningitis, a highly fatal disease. The research, conducted in mice and published recently in the journal Nature, shows that bacteria exploit nerve cells in the meninges to suppress the immune response and allow the infection to spread into the brain. “We’ve identified a neuroimmune axis at the protective borders of the brain that is hijacked by bacteria to cause infection — a clever maneuver that ensures bacterial survival and leads to widespread disease,” said study senior author Isaac Chiu, associate professor of immunology in the Blavatnik Institute at HMS. Scientists have identified the maneuvers bacteria use to invade the brain and cause meningitis. Shown here are pain receptors (in red) in the brain’s protective layers, known as meninges. When activated by bacteria, pain receptors release a chemical that disables the normal protective functions of immune cells known as macrophages (in blue), weakening the brain’s defenses. Credit: Chiu Lab/Harvard Medical School The study identifies two central players in this molecular chain of events that leads to infection — a chemical released by nerve cells and an immune cell receptor blocked by the chemical. The study experiments show that blocking either one can interrupt the cascade and thwart the bacterial invasion. If replicated through further research, the new findings could lead to much-needed therapies for this hard-to-treat condition that often leaves those who survive with serious neurologic damage. Such treatments would target the critical early steps of infection before bacteria can spread deep into the brain. “The meninges are the final tissue barrier before pathogens enter the brain, so we have to focus our treatment efforts on what happens at this border tissue,” said study first author Felipe Pinho-Ribeiro, a former post-doctoral researcher in the Chiu lab, now an assistant professor at Washington University in St. Louis. A Recalcitrant Disease in Need of New Treatments More than 1.2 million cases of bacterial meningitis occur globally each year, according to the U.S. Centers for Disease Control and Prevention. Untreated, it kills seven out of 10 people who contract it. Treatment can reduce mortality to three in 10. However, among those who survive, one in five experience serious consequences, including hearing or vision loss, seizures, chronic headache, and other neurological problems. Current therapies — antibiotics that kill bacteria and steroids that tame infection-related inflammation — can fail to ward off the worst consequences of the disease, particularly if therapy is initiated late due to delays in diagnosis. Inflammation-reducing steroids tend to suppress immunity, weakening protection further and fueling infection spread. Thus, physicians must strike a precarious balance: They must rein in brain-damaging inflammation with steroids, while also ensuring that these immunosuppressive drugs do not further disable the body’s defenses. The need for new treatments is magnified by the lack of a universal meningitis vaccine. Many types of bacteria can cause meningitis, and designing a vaccine for all possible pathogens is impractical. Current vaccines are formulated to protect against only some of the more common bacteria known to cause meningitis. Vaccination is recommended only for certain populations deemed at high risk for bacterial meningitis. Additionally, vaccine protection wanes after several years. Chiu and colleagues have long been fascinated by the interplay between bacteria and the nervous and immune systems and by how the crosstalk between nerve cells and immune cells may either precipitate or ward off disease. Previous research led by Chiu has shown that the interaction between neurons and immune cells plays a role in certain types of pneumonia and in flesh-destroying bacterial infections. This time around, Chiu and Pinho-Ribeiro turned their attention to meningitis — another condition in which they suspected the relationship between nervous and immune systems plays a role. The meninges are three membranes that lie atop one another, wrapping the brain and spinal cord to shield the central nervous system from injury, damage, and infection. The outermost of the three layers — called dura mater — contains pain neurons that detect signals. Such signals could come in the form of mechanical pressure — blunt force from impact or toxins that make their way into the central nervous system through the bloodstream. The researchers focused precisely on this outermost layer as the site of initial interaction between bacteria and protective border tissue. Recent research has revealed that the dura mater also harbors a wealth of immune cells, and that immune cells and nerve cells reside right next to each other — a clue that captured Chiu’s and Pinho-Ribeiro’s attention. “When it comes to meningitis, most of the research so far has focused on analyzing brain responses, but responses in the meninges — the barrier tissue where infection begins — have remained understudied,” Ribeiro said. What exactly happens in the meninges when bacteria invade? How do they interact with the immune cells residing there? These questions remain poorly understood, the researchers said. How Bacteria Break Through the Brain’s Protective Layers In this particular study, the researchers focused on two pathogens —Streptococcus pneumoniae and Streptococcus agalactiae, leading causes of bacterial meningitis in humans. In a series of experiments, the team found that when bacteria reach the meninges, the pathogens trigger a chain of events that culminates in disseminated infection. First, researchers found that bacteria release a toxin that activates pain neurons in the meninges. The activation of pain neurons by bacterial toxins, the researchers noted, could explain the severe, intense headache that is a hallmark of meningitis. Next, the activated neurons release a signaling chemical called CGRP. CGRP attaches to an immune-cell receptor called RAMP1. RAMP1 is particularly abundant on the surface of immune cells called macrophages. Once the chemical engages the receptor, the immune cell is effectively disabled. Under normal conditions, as soon as macrophages detect the presence of bacteria, they spring into action to attack, destroy, and engulf them. Macrophages also send distress signals to other immune cells to provide a second line of defense. The team’s experiments showed that when CGRP gets released and attaches to the RAMP1 receptor on macrophages, it prevented these immune cells from recruiting help from fellow immune cells. As a result, the bacteria proliferated and caused widespread infection. To confirm that the bacterially induced activation of pain neurons was the critical first step in disabling the brain’s defenses, the researchers checked what would happen to infected mice lacking pain neurons. Mice without pain neurons developed less severe brain infections when infected with two types of bacteria known to cause meningitis. The meninges of these mice, the experiments showed, had high levels of immune cells to combat the bacteria. By contrast, the meninges of mice with intact pain neurons showed meager immune responses and far fewer activated immune cells, demonstrating that neurons get hijacked by bacteria to subvert immune protection. To confirm that CGRP was, indeed, the activating signal, researchers compared the levels of CGRP in meningeal tissue from infected mice with intact pain neurons and meningeal tissue from mice lacking pain neurons. The brain cells of mice lacking pain neurons had barely detectable levels of CGRP and few signs of bacterial presence. By contrast, meningeal cells of infected mice with intact pain neurons showed markedly elevated levels of both CGRP and more bacteria. In another experiment, the researchers used a chemical to block the RAMP1 receptor, preventing it from communicating with CGRP, the chemical released by activated pain neurons. The RAMP1 blocker worked both as preventive treatment before infection and as a treatment once infection had occurred. Mice pretreated with RAMP1 blockers showed reduced bacterial presence in the meninges. Likewise, mice that received RAMP1 blockers several hours after infection and regularly thereafter had milder symptoms and were more capable of clearing bacteria, compared with untreated animals. A Path to New Treatments The experiments suggest drugs that block either CGRP or RAMP1 could allow immune cells to do their job properly and increase the brain’s border defenses. Compounds that block CGRP and RAMP1 are found in widely used drugs to treat migraine, a condition believed to originate in the top meningeal layer, the dura mater. Could these compounds become the basis for new medicines to treat meningitis? It’s a question the researchers say merits further investigation. One line of future research could examine whether CGRP and RAMP1 blockers could be used in conjunction with antibiotics to treat meningitis and augment protection. “Anything we find that could impact treatment of meningitis during the earliest stages of infection before the disease escalates and spreads could be helpful either to decrease mortality or minimize the subsequent damage,” Pinho-Ribeiro said. More broadly, the direct physical contact between immune cells and nerve cells in the meninges offers tantalizing new avenues for research. “There has to be an evolutionary reason why macrophages and pain neurons reside so closely together,” Chiu said. “With our study, we’ve gleaned what happens in the setting of bacterial infection, but beyond that, how do they interact during viral infection, in the presence of tumor cells, or the setting of brain injury? These are all important and fascinating future questions.” Reference: “Bacteria hijack a meningeal neuroimmune axis to facilitate brain invasion” by Felipe A. Pinho-Ribeiro, Liwen Deng, Dylan V. Neel, Ozge Erdogan, Himanish Basu, Daping Yang, Samantha Choi, Alec J. Walker, Simone Carneiro-Nascimento, Kathleen He, Glendon Wu, Beth Stevens, Kelly S. Doran, Dan Levy and Isaac M. Chiu, 1 March 2023, Nature. DOI: 10.1038/s41586-023-05753-x Co-authors included Liwen Deng, Dylan Neel, Himanish Basu, Daping Yang, Samantha Choi, Kathleen He, Alec Walker, Glendon Wu, and Beth Stevens of Harvard Medical School; Ozge Erdogan, of the Harvard School of Dental Medicine; Kelly Doran of the University of Colorado; Dan Levy and Simone Carneiro-Nascimento of Beth Israel Deaconess Medical Center. This work was supported by National Institutes of Health (NIH) grants R01AI130019, R01DK127257, 2R01NS078263, 5R01NS115972, P50MH112491, R01NS116716, T32GM007753; by the Burroughs Wellcome Fund, the Kenneth Rainin Foundation, the Food Allergy Science Initiative, the Fairbairn Lyme Initiative; with additional support from the Harvard Medical School Immunology Undergraduate Summer Program. Chiu and Ribeiro are inventors on U.S. patent application 2021/0145937A1, “Methods and Compositions for Treating a Microbial Infection,” which includes targeting CGRP and its receptors to treat infections. The Chiu lab receives research support from Abbvie/Allergan and Moderna, Inc.
DVDV1551RTWW78V
High-performance insole OEM China 》committed to ESG, comfort, and your brand is successCushion insole OEM solution Thailand 》tailored support for growing product linesTaiwan flexible graphene product manufacturing 》long-term production solutions with flexible volume